SERA PROGNOSTICS, INC. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
Sera Prognostics reported Q2 2026 revenue of $30,000 (vs. $17,000 in Q2 2025) and net loss of $9.1 million (vs. $8.0 million in Q2 2025). Illinois enacted Public Act 104-0470 in June 2026 mandating Medicaid coverage for PreTRM biomarker testing, covering ~50,000 annual Medicaid births. The company ended Q2 with $80.3 million in cash/securities and launched a fourth payer partnership program, with 20+ active payer discussions across 20+ states.
Why this rating
Illinois Medicaid mandate and payer partnerships are operationally positive but revenue remains minimal ($30K quarterly). Cash runway to 2029 is adequate. Company is early-stage; growth is dependent on adoption execution.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.